Comparison
CJC-1295 vs. Retatrutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
no data
2381089-83-2
Molecular weight
3647.3 g/mol
4731.6 g/mol
Half-life
144 h
144 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACY-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSMechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
5
of which in humans
2
4
Effects recorded
3
4
Open conflicts
1
0
Documented adverse events
3
2